Jon Congleton
2023 - Mineralys Therapeutics
In 2023, Jon Congleton earned a total compensation of $5.4M as Chief Executive Officer at Mineralys Therapeutics, a 208% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $245,575 |
|---|---|
| Option Awards | $4,579,482 |
| Salary | $517,000 |
| Other | $13,200 |
| Total | $5,355,257 |
Congleton received $4.6M in option awards, accounting for 86% of the total pay in 2023.
Congleton also received $245.6K in non-equity incentive plan, $517K in salary and $13.2K in other compensation.
Rankings
In 2023, Jon Congleton's compensation ranked 104th out of 2,996 executives tracked by ExecPay. In other words, Congleton earned more than 96.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 104 out of 2,996 | 97th |
Division Manufacturing | 57 out of 1,640 | 97th |
Major group Chemicals And Allied Products | 34 out of 909 | 96th |
Industry group Drugs | 33 out of 872 | 96th |
Industry Pharmaceutical Preparations | 22 out of 630 | 97th |
Source: SEC filing on April 9, 2024.
Congleton's colleagues
We found two more compensation records of executives who worked with Jon Congleton at Mineralys Therapeutics in 2023.